低剂量非布司他对高尿酸血症伴痛风患者抑制炎性因子、血管内皮损伤因子表达的影响

Effects of Low-dose Febuxostat on the Expression of Inflammatory Factors and Vascular Endothelial Injury Factors in Patients with Hyperuricemia and Gout

目的对高尿酸血症伴痛风患者采用低剂量非布司他治疗对其炎性因子、血管内皮损伤因子的影响进行探究。方法选择该院2018年1月—2019年8月收治的高尿酸症伴痛风患者82例作为该次研究纳入的研究对象,按照随机数表法将其划分为高剂量组和低剂量组,每组41例。采用低剂量非布司他对低剂量组进行治疗,采用高剂量非布司他对高剂量组进行治疗,对两组患者的疗效及炎性因子、血管内皮损伤因子的变化进行观察和比较。结果经2个月治疗后,低剂量组的总有效率80.5%与高剂量组78.0%比较差异无统计学意义(χ^(2)=0.074,P>0.05);低剂量组的肿瘤坏死因子(29.4±5.8)ng/L、白细胞介素(30.9±2.8)ng/L、内皮素-1(28.1±4.4)ng/L、可溶性细胞间黏附分子-1(294.1±80.3)ng/mL与高剂量组(30.5±6.2)ng/L、(31.5±3.2)ng/L、(28.2±4.9)ng/L、(298.6±73.5)ng/mL比较差异无统计学意义(t=0.830、0.904、0.097、0.265,P>0.05);低剂量组的不良反应率7.3%低于高剂量组24.4%,差异有统计学意义(χ^(2)=4.479,P<0.05)。结论针对高尿酸血症伴痛风患者采用低剂量非布司他治疗效果确切,能够有效控制其炎性因子水平,并且提高其血管内皮细胞功能,而且不良反应更少,具有很高的安全性。

Objective To explore the effects of low-dose febuxostat treatment on inflammatory factors and vascular endothelial injury factors in patients with hyperuricemia and gout.Methods From January 2018 to August 2019,a total of 82 patients with hyperuricemia and gout in the hospital were selected as the subjects of this study.They were divided into high-dose group and low-dose group according to the random number table method,41 cases in each group.Low-dose febuxostat was used to treat the low-dose group,and high-dose febuxostat was used to treat the high-dose group.The curative effect and the changes of inflammatory factors and vascular endothelial injury factors of the two groups were observed and compared.Results After 2 months of treatment,the total efficiency of 80.5%in the low-dose group was not statistically significant compared with 78.0%in the high-dose group.The difference was not statistically significant(χ^(2)=0.074,P>0.05);tumors in the low-dose group Necrosis factor(29.4±5.8)ng/L,interleukin(30.9±2.8)ng/L,endothelin-1(28.1±4.4)ng/L,soluble intercellular adhesion molecule-1(294.1±80.3)ng/mL and high-dose group(31.5±3.2)ng/L,(30.9±2.8)ng/L,(28.2±4.9)ng/L and(298.6±73.5)ng/mL was not significant.The difference was not statistically significant(t=0.830,0.904,0.097,0.265,P>0.05);the adverse reaction rate of the low-dose group was 7.3%lower than that of the high-dose group 24.4%,the difference was statistically significant(χ^(2)=4.479,P<0.05).Conclusion Low-dose febuxostat is effective in treating patients with hyperuricemia and gout.It can effectively control the level of inflammatory factors and improve the function of vascular endothelial cells,with fewer adverse reactions and high safety.